Altasciences — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$4,670,631	22
2023	Research	$4,394,694	22
2022	Research	$186,333	2
2019	Research	$220,023	1

Breakdown

Who paid Research payments · program years 2019–2024

Novo Nordisk AS $7,826,051 36 payments
E.R. Squibb & Sons, L.L.C. $824,738 3 payments
Biogen, Inc. $413,300 4 payments
Amneal Pharmaceuticals LLC $220,023 1 payment
AbbVie, Inc. $185,991 2 payments
Novartis Pharmaceuticals Corporation $1,578 1 payment

Studies the money was for Research payments · program years 2019–2024

Nn9924-4891 $7,217,197 27 payments
A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted from Drug Substance of a New Abatacept Drug Substance Process J Relative to the Current Abatacept Drug Process F in Healthy Participants $681,847 1 payment
Nn9535-7560 $608,854 9 payments
A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study with RTA 901 L-proline Cocrystal in Healthy Subjects $349,803 1 payment
Single Dose Crossover Comparative Bioavailability Study of Morphine Sulfate ER Capsules USP 100mg Tablets in Healthy Adult Subjects under Fasting State $220,023 1 payment
A First-in-Human Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses of ABBV-668 in Western and Asian Subjects and to Evaluate the Effects of Food and Itraconazole on the Safety and Pharmacokinetics of ABBV-668 in Western Subjects $184,755 1 payment
A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted from Drug Substance of a New Abatacept Drug Substance Process J Relative to th $126,892 1 payment
A Phase 1, Single Dose, Comparative Bioavailability Study of Two Different Forms of RTA 901 L-proline Cocrystal in Healthy Subjects $44,082 1 payment
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) $16,708 1 payment
SAD/MAD/FE/FB - A Phase 1, Randomized, Multi-Part, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986421 in Healthy Participants $16,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.